- Home
- IMAB
IMAB
I-MAB
as 05-06-2025 1:38pm EST
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 73.9M | IPO Year: | 2020 |
| Target Price: | $5.50 | AVG Volume (30 days): | 218.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $2.00 | Next Earning Date: | 04-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
Zacks
22 days ago
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
Zacks
25 days ago
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
GlobeNewswire
a month ago
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
MT Newswires
a month ago
I-Mab Gets Nasdaq Noncompliance Notice on Bid Price Requirement
GlobeNewswire
a month ago
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
GlobeNewswire
2 months ago
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.